Colombia Biologics Contract Manufacturing Market Size & Outlook

The biologics contract manufacturing market in Colombia is expected to reach a projected revenue of US$ 310.3 million by 2030. A compound annual growth rate of 9.8% is expected of Colombia biologics contract manufacturing market from 2021 to 2030.
Revenue, 2020 (US$M)
$121.4
Forecast, 2030 (US$M)
$310.3
CAGR, 2021 - 2030
9.8%
Report Coverage
Colombia

Colombia biologics contract manufacturing market, 2018-2030 (US$M)

Colombia

Colombia biologics contract manufacturing market highlights

  • The Colombia biologics contract manufacturing market generated a revenue of USD 121.4 million in 2020 and is expected to reach USD 310.3 million by 2030.
  • The Colombia market is expected to grow at a CAGR of 9.8% from 2021 to 2030.
  • In terms of segment, mabs was the largest revenue generating product in 2020.
  • MABs is the most lucrative product segment registering the fastest growth during the forecast period.

Biologics contract manufacturing market data book summary

Market revenue in 2020USD 121.4 million
Market revenue in 2030USD 310.3 million
Growth rate9.8% (CAGR from 2020 to 2030)
Largest segmentMabs
Fastest growing segmentMABs
Historical data2018 - 2019
Base year2020
Forecast period2021 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMABs, Recombinant Protein
Key market players worldwideWuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, Boehringer Ingelheim, Lonza Group Ltd, AbbVie Inc, Catalent Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Abzena, Samsung BioLogics

Other key industry trends

  • In terms of revenue, Colombia accounted for 1.0% of the global biologics contract manufacturing market in 2020.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil biologics contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
  • Brazil is the fastest growing regional market in Latin America and is projected to reach USD 788.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biologics Contract Manufacturing Market Companies

Name Profile # Employees HQ Website

Colombia biologics contract manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract manufacturing market will help companies and investors design strategic landscapes.


Mabs was the largest segment with a revenue share of 57.91% in 2020. Horizon Databook has segmented the Colombia biologics contract manufacturing market based on mabs, recombinant protein covering the revenue growth of each sub-segment from 2018 to 2030.


  • Colombia Biologics Contract Manufacturing Product Outlook (Revenue, USD Million, 2018-2030)
    • MABs
    • Recombinant Protein
    • Others
  • Colombia Biologics Contract Manufacturing Indication Outlook (Revenue, USD Million, 2018-2030)
    • Oncology
    • Immunological Disorders
    • Cardiovascular Disorders (CVDs)
    • Hematological Disorders
    • Others

Reasons to subscribe to Colombia biologics contract manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Colombia biologics contract manufacturing market databook

  • Our clientele includes a mix of biologics contract manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Colombia biologics contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Colombia biologics contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Colombia biologics contract manufacturing market size, by product, 2018-2030 (US$M)

Colombia Biologics Contract Manufacturing Market Outlook Share, 2020 & 2030 (US$M)

Colombia biologics contract manufacturing market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more